Patent ID: 6080731
Filing Date: 2000-06-27
Classification: A61P,C07H

Abstract:
A method of treating HIV infections in a patient in need thereof, comprising administering to said patient an effective amount of a dinucleoside-5',5'-P.sup.1, P.sup.2 -pyrophosphate of the formula (I): ##STR48## wherein: the symbols A and B each independently represent a 5'-C' radical of a non-naturally occurring nucleoside selected from the group consisting of thymine-3'-azido-2',3'-dideoxy-D-riboside, 5'-fluorouracil-2'-deoxy-D-riboside, uracil-3'-azido-2',3'-dideoxy-D-riboside, guanine-2',3'-dideoxy-D-riboside, hypoxanthine-2',3'-dideoxy-D-riboside, cytosine-2',3'-dideoxy-D-riboside, and adenine-2',3'-dideoxy-D-riboside;the symbols X each independently represent oxygen or sulfur;the symbols R and R.sub.1 each independently represent hydrogen or an alkyl group of from 1 to 10 carbon atoms, which may optionally contain an unsaturation and/or one or two substituents selected from the group consisting of hydroxy, mercapto, chloro, iodo, fluoro, bromo, amino, (C.sub.1 -C.sub.4)alkylamino, di-(C.sub.1 -C.sub.4)alkylamino, (C.sub.1 -C.sub.4)alkoxy and (C.sub.1 -C.sub.4)alkylthio;and the addition salts of the dinucleoside-5',5'-P.sup.1, P.sup.2 -pyrophosphates of formula (I) wherein R and/or R.sub.1 represent hydrogen with bases providing biologically acceptable cations, wherein said dinucleoside-5',5'-P.sup.1, P.sup.2 -pyrophosphate is encapsulated into a biological carrier.